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Abstract
Background: Epidemics caused by highly pathogenic avian influenza virus (HPAIV) are a
continuing threat to human health and to the world's economy. The development of approaches,
which help to understand the significance of structural changes resulting from the alarming
mutational propensity for human-to-human transmission of HPAIV, is of particularly interest. Here
we compare informational and structural properties of the hemagglutinin (HA) of H5N1 virus and
human influenza virus subtypes, which are important for the receptor/virus interaction.
Results: Presented results revealed that HA proteins encode highly conserved information that
differ between influenza virus subtypes H5N1, H1N1, H3N2, H7N7 and defined an HA domain
which may modulate interaction with receptor. We also found that about one third of H5N1
viruses which are isolated during the 2006/07 influenza outbreak in Egypt possibly evolve towards
receptor usage similar to that of seasonal H1N1.
Conclusion: The presented results may help to better understand the interaction of influenza
virus with its receptor(s) and to identify new therapeutic targets for drug development.
Background
Influenza is currently considered as one of the most
severe threats to human health and animal welfare. The
highly pathogenic avian influenza (HPAIV) H5N1
viruses have been isolated from avian species in more
than 50 countries. As of January 2008, 349 human H5N1
infections have been reported to the World Health
Organization (WHO) [1]. Of these 349 cases, 216
patients have died (62%) and there has been no decline
in mortality rate. Because the virus has evolving
antigenicity for which humans may not have a pre-
existing immunity, the conditions for a possible pan-
demic exist.
The entry of influenza virus into susceptible cells is
mediated by the viral hemagglutinin (HA) membrane
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glycoprotein which binds sialic acids of cell-surface
glycoproteins and glycolipids. The binding preference
of a given HA for different receptors correlates to some
extent with the species specificity for infection. Human
isolates preferentially bind to receptors with a2,6
linkages to galactose (SAa2,6Gal), whereas avian isolates
prefer a2,3 linkages (SAa2,3Gal) [2-6]. A change in
receptor preference is, however not necessary since the
lower respiratory tract also expresses a 2.3 receptors [7].
It has also been reported that influenza virus can infect
host cells via a sialic acid-independent pathway, either
directly or in a multistage process [8]. It has been
speculated that sialic acid enhances virus binding to
secondary receptors that mediate entry [8].
Several approaches, such as structural analyses, model
protein evolution, andmathematical modeling have been
taken to study the antigenic drift and shift of influenza A
viruses (for review see Ref. [23] and references therein).
All of these approaches trace changes in HA but they do
not allow precise assessment of biological consequences.
Here we applied the informational spectrum method
(ISM), which is a theoretical approach to investigate the
periodicity of structural motifs with defined physico-
chemical characteristics that determinate biological prop-
erties of proteins [9]. The protein sequence is encoded
numerically by assigning to each amino acid its electron-
ion interaction potential (EIIP), which describes the
average energy states of valence electrons in an amino
acid. By using the discrete Fourier transform (DFT), the
numerical sequence is transformed into a frequency
domain to create an ISM spectrum. It has been pointed
out that the Fourier spectra of protein sequences involved
in mutual interaction are similar and this similarity is
represented by the common frequency component [9].
The ISM spectrum is a contribution of all individual
amino acids in the sequence. Therefore, once the
characteristic frequency has been identified it is possible
to use ISM to determine how the substitution of an amino
acid changes the frequency and influences the biological
activity of the protein. Using this bioinformatics
approach we have previously characterized the conserved
information responsible for interaction between envel-
ope glycoprotein gp120 of human immunodeficiency
virus type 1 (HIV-1) and their CD4, CCR5 and CXCR4
receptors [9-11]. By analogy with HIV-1 gp120, it can be
assumed that highly variable HA molecules of influenza
viruses also encode conserved information, which may
determine receptor-binding preferences. Identification
and characterization of this information could contribute
to a better understanding of HPAIV/host interaction.
Herewe show that theHA subunit 1 (HA1) ofH5N1 viruses
encodes specific and highly conserved information which
may determine the recognition and targeting of these HPAI
viruses to their receptor. The comparison with seasonal
strains suggests that a subset of H5N1 in Egypt may be
evolving towards an H1N1-like receptor usage.
Methods
Sequences
The HA1 sequences were retrieved from GenBank
database with following accession numbers and were
used for the results of Figure 1 and 2:
H1N1 (Figure 1d): A/Fort Monmouth/1/1947-mouse
adapted [U02464]; A/Fort Monmouth/1/1947
[U02085]; A/Lepine/1948 [AB043479]; A/TF/15/1951
[AB043480]; A/Kojiya/1/1952 [AB043482]; A/Finland/
158/1991 [L19549]; A/Taiwan/13/1954 [AB043483]; A/
Meguro/1/1956 [AB043485] ; A/Saga /2/1957
[AB043486]; A/swine/Wisconsin/1/1968 [EU139825];
A/swine/Iowa/1973 [EU139826]; A/swine/Iowa/1976/
1931 [U11858]; A/chicken/Hong Kong/14/1976
[EF679200]; A/USSR/90/1977 [DQ508897]; A/duck/
Hong Kong/717/1979 [EF679199]; A/Kiev/59/1979
[M38353]; A/turkey/Kansas/4880/1980 [EF679201]; A/
swine/Netherlands/3/1980 [U46942]; A/swine/Nether-
lands/12/1985 [U46943]; A/Singapore/6/1986
[D00406]; A/Taiwan/01/1986 [DQ508873]; A/Kamata/
Figure 1
ISM analysis of HA1 proteins of H5 influenza viruses.
(a) Consensus IS of HA1 of all H5N1 sequences in GenBank
(n = 1407); (b) IS of H5N3 (A/swan/Hokkaido/51/96), the
progenitor of H5N1, and (c) of the first isolated H5N1 virus
(A/Goose/Guangdong/1/96); (d) consensus IS of H1N1
(n = 30), (e) of H3N2 (n = 30) and (f) of H7N7 (n = 30).
BMC Structural Biology 2009, 9:21 http://www.biomedcentral.com/1472-6807/9/21
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85/1987 [AB043487]; A/SL/2/1987 [M33748]; A/Fiji/2/
1988 [L19011]; A/South Carolina/6/1988 [L19025]; A/
Franch/6908/1989 [L19016]; A/Yamagata/32/1989
[AB304820]; A/Stockholm/26/1990 [L19013]
H3N2 (Figure 1e): A/Aichi/2/1968 [EF614248]; A/England/
878/1969 [K03335]; A/Qu/7/1970 [K03338]; A/Hong
Kong/107/1971 [EF626615]; A/Udorn/307/1972
[DQ508929]; A/Port Chalmers/1/1973 [EF626618]; A/
Victoria/3/1975 [EF626609]; A/duck/Alberta/78/1976
[M73771]; A/swine/Italy/1850/1977 [DQ975252]; A/
swine/Hong Kong/81/1978 [M19057]; A/Bangkok/01/
1979 [DQ508825]; A/Shanghai/31/1980 [EF626620]; A/
swine/Italy/6/1981 [DQ975253]; A/Umea/1982/92
[AY661134]; A/swine/Ukkel/1/1984 [M73775]; A/Lenin-
grad/360/1986 [DQ508849]; A/swine/Italy/630/1987
[DQ975255]; A/Hokkaido/1/1988 [D43787]; A/Beijing/
352/1989 [D43786]; A/swine/Ange-Gardien/150/1990
[U07146]; A/Wisconsin/03/2007 [EU516105]; A/Hok-
kaido/1/1993 [D43788]; A/England/79/1994 [EF456783];
A/swine/Italy/1380-2/1995 [DQ975260]; A/Lyon/1781/96
[AF131996]; A/Nairobi/2041/2006 [EF199897]; A/
Panama/2007/1999 [DQ508865]; A/South Africa/96/
2000 [EF462562]; A/Chile/6416/2001 [DQ865972]
H5N1 (Figure 1a): All available H5N1 HA1 sequences
presented in the GenBank database (1407 entries) as of 1
February 2008.
H5N1 (Egypt-1) (Figure 2a): A/Egypt/2763-NAMRU3/
2006 [EF042614]; A/Egypt/2782-NAMRU3/2006
[DQ464377] ; A /Egyp t /12374 -NAMRU3/2006
[EF061116]; A/Chicken/Egypt/5611NAMRU3-AN/2006
[DQ837588]; A/Chicken/Egypt/5610NAMRU3-F3/2006
[DQ837587]; A/Turkey/Egypt/5613NAMRU3-T/2006
[DQ837590]; A/Chicken/Egypt/5612NAMRU3-S/2006
[DQ837589]; A/chicken/Egypt/960N3-004/2006
[DQ447199]; A/chicken/Egypt/10845-NAMRU3/2006
[ E F042622 ] ; A / c h i c k en / E g yp t / 2 253 - 1 / 2006
[DQ862001 ] ; A / t u r k e y / E g y p t / 2 2 53 - 2 / 2 006
[CY020653]; A/chicken/Egypt/1300-NAMRU3/2007
[EF441280]; A/chicken/Egypt/1078-NAMRU3/2006
[EF441276]; A/chicken/Egypt/1890N3-HK45/2007
[EF469654]; A/chicken/Egypt/1891N3-CLEVB/2007
[EF469659]; A virus (A/Egypt/1902-NAMRU3/2007
[EF535820]; A/Egypt/5614-NAMRU3/2006 [EF042621];
A/Egypt/2256-NAMRU3/2007 [EF535821]; A/Egypt/
2321-NAMRU3/2007 [EF535822]; A/Egypt/2331-
NAMRU3/2007 [EF535823]; A/Egypt/2616-NAMRU3/
2007 [EF535824]; A/Egypt/2620-NAMRU3/2007
[EF535825]; A/Egypt/3458-NAMRU3/2006 [EF042619];
A/chicken/Egypt/R1/2006 [EU183327]; A/duck/Egypt/
F5/2006 [EU183325]; A/chicken/Egypt/F4/2006
[EU183324]; A/chicken/Egypt/F3/2006 [EU183323]; A/
turkey/Egypt/F2/2006 [EU183322]; A/Egypt/5494-
NAMRU3/2006 [EF042620]; A/Egypt/3105-NAMRU3/
2006 [EF042618]; A/Egypt/2630-NAMRU3/2007
[ EU095026 ] ; A / E g y p t / 2 7 50 -NAMRU3 / 2007
[ EU095028 ] ; A / E g y p t / 2 7 51 -NAMRU3 / 2007
[ EU095029 ] ; A / E g y p t / 4 0 82 -NAMRU3 / 2007
[ EU095031 ] ; A / E g y p t / 4 2 26 -NAMRU3 / 2007
[ EU095032 ] ; A / E g y p t / 6 2 51 -NAMRU3 / 2007
[ EU095033 ] ; A / E g y p t / 4 0 81 -NAMRU3 / 2007
[ EU095030 ] ; A / E g y p t / 2 7 86 -NAMRU3 / 2006
[EF042616]; A/Egypt/2783-NAMRU3/2006 [EF042615];
A/chicken/Egypt/07181-NLQP/2007 [EU496387]; A/
chicken/Egypt/07201-NLQP/2007 [EU496388]; A/
chicken/Egypt/07202-NLQP/2007 [EU496389]; A/tur-
key/Egypt/07203-NLQP/2007 [EU496390]; A/duck/
Egypt/07264S-NLQP/2007 [EU496391]; A/goose/
Egypt/07364S-NLQP/2007 [EU496393]; A/turkey/
Egypt/07444S-NLQP/2007 [EU496394]; A/chicken/
Egypt/07632S-NLQP/2007 [EU496395]; A/chicken/
Egypt/07665S-NLQP/2007 [EU496396]; A/chicken/
Egypt/07701S-NLQP/2007 [EU496397]; A/chicken/
Egypt/06553-NLQP/2006 [EU496383]; A/chicken/
Egypt/06612-NLQP/2006 [EU496384]; A/quail/Egypt/
07120-NLQP/2007 [EU496385]; A/chicken/Egypt/
07125-NLQP/2007 [EU496386]
H5N1 (Egypt-2) (Figure 2b): A/Egypt/0636-NAMRU3/
2007 [EF382359]; A/Egypt/14725-NAMRU3/2006
[EF200513]; A/duck/Egypt/2253-3/2006 [DQ862002];
A/duck/Egypt/1301-NAMRU3/2007 [EF441281]; A/
chicken/Egypt/1081-NAMRU3/2006 [EF441279]; A/
chicken/Egypt/1080-NAMRU3/2006 [EF441278]; A/
Figure 2
The ISM analysis of HA1 proteins of H5N1 viruses
isolated in Egypt in 2006/2007. (a) consensus IS of Egypt-
1 and (b) of Egypt-2 strains, (c) IS of a representative Egypt-1
(A/teal/Egypt/9885-NAMRU3/2005) and (d) Egypt-2 virus
(A/chicken/Egypt/R6/2007).
BMC Structural Biology 2009, 9:21 http://www.biomedcentral.com/1472-6807/9/21
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chicken/Egypt/1079-NAMRU3/2007 [EF441277]; A/
Egypt/14724-NAMRU3/2006 [EF200512]; A/chicken/
Egypt/1889N3-SM26/2007 [EF469653]; A/chicken/
Egypt/1892N3-HK49/2007 [EF469660]; A/duck/Egypt/
1888N3-SM25/2007 [EF469657]; A/Egypt/1394-
NAMRU3/2007 [EF535817]; A/Egypt/1604-NAMRU3/
2007 [EF535818]; A/Egypt/1731-NAMRU3/2007
[EF535819]; A/Egypt/2621-NAMRU3/2007 [EF535826];
A/goose/Egypt/R4/2007 [EU183330]; A/chicken/Egypt/F6/
2007 [EU183326]; A/chicken/Egypt/R6/2007 [EU183332];
A/duck/Egypt/R5/2007 [EU183331]; A/chicken/Egypt/R3/
2007 [EU183329]; A/chicken/Egypt/R2/2007 [EU183328];
A/Egypt/2629-NAMRU3/2007 [EU095025]; A/Egypt/2631-
NAMRU3/2007 [EU095027]; A/Egypt/2947-NAMRU3/
2006 [EF042617]; A/chicken/Egypt/9385NAMRU3-
CLEVB125/2007 [EU371910]; A/chicken/Egypt/
9390NAMRU3-CLEVB157/2007 [EU371915]; A/chicken/
Egypt/9392NAMRU3-CLEVB167/2007 [EU371917]; A/
ch i cken/Egypt /9387NAMRU3-CLEVB148/2007
[EU371912]; A/chicken/Egypt/3051NAMRU3-CLEVB78/
2007 [EU371905]; A/chicken/Egypt/9386NAMRU3-
CLEVB/136/2007 [EU371911]; A/chicken/Egypt/
9391NAMRU3-CLEVB158/2007 [EU371916];
H7N7 (Figure 1f): A/chicken/Victoria/75 [Z47199]; A/
tern/Potsdam/342/6/79 [U20470]; A/chicken/Jena/
1816/87 [U20469] ; A/swan/Potsdam/63/6/81
[U20467]; A/duck/Heinersdorf/S495/6/86 [U20465]; A/
equine/London/1416/1973 [M58657]; A/starling/Vic-
toria/1/1985 [M17736]; A/goose/Leipzig/137/8/1979
[L43913]; A/seal/Mass/1/80 [K00429]; A/chicken/Neth-
erlands/03010132/03 [EF015551]; A/mallard/Italy/
4810-7/2004 [DQ838514]; A/Mallard/Sweden/107/02
[AY999991]; A/equine/Santiago/77 [AY383756]; A/
chicken/Netherlands/1/03 [AY338458]; A/chicken/Ger-
many/R28/03 [AJ620350]; A/turkey/Ireland/PV8/95
[AJ704799] ; A/os t r i ch/South Afr i ca/M320/96
[AF202253]; A/macaw/England/626/80 [AF202250]; A/
chicken/Ireland/1733/89 [AF202239]; A/non-psittacine/
England-Q/1985/89 [AF202240]; A/turkey/Ireland/
PV74/1995 [AF028021] ; A/England/268/1996
[AF028020]; A/duck/Jiangxi/1814/03 [EU158103]; A/
duck/Jiangxi/1742/03 [EU158108]; A/duck/Jiangxi/
1786/03 [EU158102]; A/mallard/Italy/299/05
[EU158104]; A/duck/Jiangxi/1760/03 [EU158101];
H1N1 (Spanish flu) (Figure 3): A/South Carolina/1/18
[AF117241]; A/New_York/1/18 [AF116576]; A/Brevig_-
Mission/1/18 [AF116575]
Informational spectrum method
The surface complementarity between interacting bio-
molecules, which was originally proposed by Emil
Fischer in 1894, together with the collision theory,
assuming that the first contact between interacting
molecules is achieved accidentally by the thermal
motions that cause molecular wander, represents the
fundamental basis for our current understanding of
intermolecular interaction in biological systems. Accord-
ing to this concept, the diffusion-limited association rate
constant, calculated by the Smoluchowski's equation is
~106 M-1s-1 for a protein-ligand and ~103 M-1s-1 for a
protein-protein interaction. On the other hand, the real
protein-protein association generally occurs at rates that
are 103 to 104 times faster than would be predicted from
a simple 3D "random diffusion" model [12].
In order to overcome the discrepancy between theoreti-
cally estimated values and real values of the associated
rate constant for a protein-protein interaction, the model
for interaction between biological molecules based on
frequency-selective long-range attractive forces which are
efficient at a distance longer than one linear dimension
of the interacting macromolecules (102 – 103 Å), has
been proposed [13,14]. It has been shown that the
number of valence electrons and EIIP, representing the
main energy term of the valence electrons, are essential
physical parameters of biological molecules determining
their long-range properties of biological molecules. The
EIIP can be determined for organic molecules by the
following simple equation derived from the "general
model pseudopotential" [15,16]:
W Z Z= ∗ ∗0 25 1 04 2. sin( . ) /p p (1)
where Z* is the average quasivalence number (AQVN)
determined by
Figure 3
Consensus IS of HA1 from three Spanish flu H1N1
viruses.
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Z n Z Nm i i* /= ∑ (2)
where Zi is the valence number of the i-th atomic
component, ni is the number of atoms of the i-th
component, m is the number of atomic components in
the molecule, and N is the total number of atoms. The
EIIP values calculated according to equations (1) and (2)
are in Rydbergs (Ry).
Using the concept of the long-range forces which
increase numbers of productive collisions between
interacting biomolecules and the EIIP values of amino
acids, the informational spectrum method (ISM), for
analysis of protein-protein interaction and the relation-
ship between structure and function of proteins, was
developed. This virtual spectroscopy method comprises
three basic steps:
Transformation of the alphabetic code of the primary
structure into a sequence of numbers by assigning to
each amino acid or nucleotide a corresponding numer-
ical value representing the electron-ion interaction
potential.
Conversion of the obtained numerical sequence by
Fourier transformation into the informational spectrum
(IS).
Cross-spectral analysis which allows identification of
frequency components in the informational spectrum of
molecules which are important for their biological
function or interaction with other molecules.
The physical and mathematical basis of ISM was
described in detail elsewhere [17-20], and here we will
only present this bioinformatics method in brief. A
sequence of N residues is represented as a linear array of
N terms, with each term given a weight. The weight
assigned to a residue is EIIP (Table 1). In this way the
alphabetic code is transformed into a sequence of
numbers. The obtained numerical sequence, represent-
ing the primary structure of protein, is then subjected to
a DFT, which is defined as follows:
X n m e n Nj N nm( ) ( ) , , , ..., /( / )= ∑ × =− 2 1 2 2 (3)
where x(m) is the m-th member of a given numerical
series, N is the total number of points in this series, and
X(n) are DFT coefficients. These coefficients describe the
amplitude, phase and frequency of sinusoids, which
comprise the original signal. The absolute value of
complex DFT defines the amplitude spectrum and the
phase spectrum. The complete information about the
original sequence is contained in both spectral functions.
However, in the case of protein analysis, relevant
information is presented in an energy density spectrum
[17,18], which is defined as follows:
S n X n X n X n n N( ) ( ) *( ) | ( ) | , , , ..., / .= = =2 1 2 2 (4)
In this way, sequences are analyzed as discrete signals. It is
assumed that their points are equidistant with the distance
d = 1. The maximal frequency in a spectrum defined in this
way is F = 1/2d = 0.5. The frequency range is independent of
the total number of points in the sequence. The total
number of points in a sequence influences only the
resolution of the spectrum. The resolution of the N-point
sequence is 1/n. The n-th point in the spectral function
corresponds to a frequency f(n) = nf = n/N. Thus, the initial
information defined by the sequence of amino acids can
now be presented in the form of IS, representing a series of
frequencies and their amplitudes.
The IS frequencies correspond to distribution of struc-
tural motifs with defined physicochemical properties
determining a biological function of a protein. When
comparing proteins, which share the same biological or
biochemical function, the ISM technique allows detec-
tion of code/frequency pairs which are specific for their
common biological properties, or which correlate with
their specific interaction. This common informational
characteristic of sequences is determined by a cross-
spectrum or consensus informational spectrum (con-
sensus IS). A consensus IS of N spectra is obtained by the
following equation:
C j S i j( ) ( , )= ∏ (5)
Table 1: The electron- ion interaction potential (EIIP) of amino
acids used to encode amino acids.
Amino acid EIIP [Ry]
Leu 0.0000
Ile 0.0000
Asn 0.0036
Gly 0.0050
Glu 0.0057
Val 0.0058
Pro 0.0198
His 0.0242
Lys 0.0371
Ala 0.0373
Tyr 0.0516
Trp 0.0548
Gln 0.0761
Met 0.0823
Ser 0.0829
Cys 0.0829
Thr 0.0941
Phe 0.0946
Arg 0.0959
Asp 0.1263
BMC Structural Biology 2009, 9:21 http://www.biomedcentral.com/1472-6807/9/21
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where Π (i, j) is the j-th element of the i-th power
spectrum and C(j) is the j-th element of consensus IS.
Thus, consensus IS is the Fourier transform of the
correlation function for the spectrum. In this way, any
spectral component (frequency) not present in all
compared IS is eliminated. Peak frequencies in con-
sensus IS are common frequency components for the
analyzed sequences. A measure of similarity for each
peak is a signal-to-noise ratio (S/N), which represents a
ratio between signal intensity at one particular IS
frequency and the main value of the whole spectrum.
If one calculates a consensus IS for a group of proteins,
which have different primary structures, and finds strictly
defined peak frequencies, it means that the analyzed
proteins participate in mutual interaction or have a
common biological function.
The ISM was successfully applied in structure-function
analysis of different protein sequences and de novo
design of biologically active peptides (for review see
Refs. 10 and 20), assessment of biological effects of
mutations [21] and prediction of new protein interactors
[22].
Results
To identify conserved information encoded by HA1
proteins, we performed a cross-spectral analysis of all
H5N1 HA1 amino acid sequences in GenBank (1407
entries). Figure 1a shows that the consensus IS of these
sequences contains only one peak of the frequency F
(0.076). According to the ISM concept, this information
represents the long-range component of the protein-
protein interaction between HA1 and a putative partner,
such as a receptor. Figures 1b and 1c show the IS of HA1
of the H5N3 virus A/swan/Hokkaido/51/96, the putative
progenitor of the HPA1 H5N1 subtype, and of the first
H5N1 virus isolated in China 2006 (A/Goose/Guang-
dong/1/96) [24]. Both of these IS have a dominant peak
at the same characteristic frequency F(0.076), demon-
strating that HA of these two viruses encode the same
information as the H5N1 HA1 shown in Figure 1a. The
computer scanning survey of the primary structure of
H5N1 HA1 showed that the main contribution to
information represented by the frequency F(0.076)
comes from the domain (denoted VIN1) located in the
N-terminus of the protein which encompasses residues
42 – 75 of the mature protein (Table 2, Figure 4).
Interestingly, this domain of H5N1 HA1 is highly
conserved in all H5N1 viruses.
Next, we performed the ISM analysis of HA1 molecules
of seasonal viruses H1N1 (n = 29) and H3N2 (n = 30),
as well as H7N7 viruses (n = 30), from different years
and geographic regions. Their consensus IS show
characteristic peaks of the frequencies F(0.236), F
(0.363) and F(0.285), respectively (Figures. 1d, e and
1f), distinct from the F(0.076) of H5N1 HA. This may
suggest that HA1 sequences encode information which is
specific for each of these subtypes. The domains of HA1
of H1N1, H3N2, H7N7 influenza viruses, derived from
the above frequencies are shown in Table 2 and
highlighted in the HA structural model (Figure 4).
Despite its low infectivity for humans, there has been
evidence in Egypt of several clusters of human-to-human
transmission with very high mortality rate. ISM analysis
of 95 HA sequences from Egypt 2006 and 2007 showed
that these viruses can be divided into two groups.
Consensus IS of a first group (Egypt-1) of 55 strains
contains a dominant peak of the frequency F(0.076)
which is characteristic for H5N1 HA1 and a less
prominent peak of the frequency F(0.236) which is
characteristic for H1N1 HA1 (Figure 2a). In contrast,
consensus IS of the second group (Egypt-2) (Figure 2b),
which includes 40 H5N1 HA1, contains only one
significant peak of the frequency F(0.236) corresponding
to the consensus IS of H1N1 HA1 in Figure 1d. Figures 2c
and 2d show representative IS of individual strains of
both groups. Of H5N1 viruses which were isolated in
Egypt during 2006, 76% belong to the group Egypt-1, and
24% were from the group Egypt-2. In contrast, in 2007,
48% belong to the Egypt-1 and 52% to Egypt-2.
Figure 4 shows the IS spectra of peptide VIN1 and of the
domains identified by consensus IS of H1N1, H3N2,
H5N1 and H7N7 viruses (Table 2) and the position of
these domains in the molecule. As can be seen, the
receptor targeting site of H5N1 virus from the group
Egypt-1 (A/Egypt/0636-NAMRU3/2007) is closer to
the receptor binding site than in the other viruses of
Table 2: The receptor recognition domains of HA proteins from H5N1, H1N1, H3N2 and H7N7 influenza viruses.
Strain Frequency Residues Sequence
A/Hong Kong/213/03 (H5N1) F(0.076) 42 – 75 CDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPE
A/New Caledonia/20/99 (H1N1) F(0.236) 262 – 295 SGIITSNAPMDECDAKCQTPQGAINSSLPFQNVH
A/New York/383/2004 (H3N2) F(0.363) 57 – 90 QILDGENCTLIDALLGDPQCDGFQNKKWDLFVER
A/equine/Prague/56 (H7N7) F(0.285) 28 – 61 GIEVVNATETVEQTNIPKICSKGKQTVDLGQCGL
A/Egypt/0636-NAMRU3/2007(H5N1) F(0.236) 99 – 132 EELKHLLSRINHFEKIQIIPKNSWSDHEASGVSS
A/South Carolina/1/18 (H1N1)) F(0.258) 87 – 120 NSENGTCYPGDFIDYEELREQLSSVSSFEKFEIF
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Figure 4
OverviewofH5HA trimer (PDB: 2ibx) and details of theVIN1 region. (a) Surface of HA trimer; eachmonomer has a different
color. Carbohydrates are orange. The location of receptor binding domain (orange) and VIN1 region (yellow) are highlighted only for
one monomer. (b) Ribbon representation of VIN1 region (yellow). Sulphur atoms involved in stabilization of the VIN1 region are
shown as red spheres. Figures were generated by PyMol. (c) Secondary structure and amino acid composition of H5 HIN1 region. The
consensus sequence of the VIN1 region is shown together with mutations found in 595 H5 HA sequences using BioEdit. Cystein
residues are shown in red. (d) IS of the VIN1 region. Domains of H1N1, H3N2, H5N1, H7N1 and Spanish flu identified by consensus IS
(Table 2) and their position in the 3D structure of HA1 and the IS of the peptide sequence. (e) A/New York/383/2004 (H3N2); (f) A/
equine/Prague/56 (H7N7); (g) A/Egypt/0636-NAMRU3/2007(H5N1); (h) A/New Caledonia/20/99 (H1N1); (i) A/South Carolina/1/18
(H1N1).
BMC Structural Biology 2009, 9:21 http://www.biomedcentral.com/1472-6807/9/21
Page 7 of 10
(page number not for citation purposes)
Figure 4. It may be speculated that this may affect the
efficacy of the virus/receptor interaction.
Finally, we compared informational properties of H1N1
pandemic strains from 1918 from GenBank and seasonal
H1N1 strains. The consensus IS of these pandemic isolates
(Figure 3) is characterized by a dominant peak of the
frequency F(0.258) which is different from the frequency F
(0.236) characteristic of other seasonal flu H1N1 isolates
(Figure 1d). Table 2 shows the domain corresponding to the
frequency F(0.258). In themodel of A/South Carolina/1/18
(Figure 4i) the position of this domain does not overlap
with the corresponding domain of other seasonal H1N1
strains, but overlaps with the corresponding domain of
Egypt-2 H5N1 viruses.
Discussion
The differentiation of H5N1 in an increasing number of
clades and subclades is alarming but the fundamental
changes associated with efficient human to human
transmission are poorly understood. The development
of approaches which allow the tracing and the under-
standing of such changes is of the highest priority.
To identify specific information which determines long-
range components of protein-protein interactions
between H5N1 and putatively its receptor(s), we
performed the ISM analysis of the HA1 protein. This
analysis revealed that this protein, although highly
variable, encodes conserved information, which is
represented by the IS frequency component F(0.076).
In contrast, HA1 of H1N1, H3N2 and H7N7 encode
specific information reflected by different characteristic
IS frequencies (F(0.236), F(0.363) and F(0.285), respec-
tively) corresponding to different protein domains
(Table 2).
The main information corresponding to the IS frequency
F(0.076) is contributed by the VIN1 domain located in
the N-terminus of HA1 molecule (Figure 4). This
domain is highly conserved in all H5N1 viruses. The
peptide VIN1 is located within the site E between
residues 42 and 75, one of the five major antigenic
domains of the HA molecule. In the 3D structure of HA1
the site E is located below the globular head involved in
receptor binding [5]. It was previously shown that
protein domains, which are essential for particular IS
frequency are directly involved in protein-protein inter-
action [9,22]. Therefore, we postulate that the VIN1
domain plays an important role in the recognition and
targeting between virus and receptor. For this reason,
VIN1 may represent a potential target for therapy of
H5N1 infection.
It is of note that the E site, encompassing the VIN1 domain,
is placed below the globular head of HA1 which is involved
in the receptor binding [5]. Most mutations which encode
receptor tropism [6,7] and are involved in immune
avoidance occur in this globular part of HA1 molecule.
On the other hand, mutations within the site E are rare. This
indicates that variable antigenic sites A and B located in the
globular head of HA1 could represent an immune decoy
which protects the important functional site E, determining
the conserved long-range properties of the molecule. A
similar structural organization was previously reported for
HIV-1 gp120 [11,25] and it was pointed out as an important
obstacle in development of AIDS vaccine [26-28].
H5N1 already replicates efficiently in humans, and cause
case fatality rates that are ten times higher than those
seen in the 1918 pandemic. Thus, an infectivity of H5N1
similar to seasonal flu would cause a catastrophic
pandemic. The main obstacle for this worst case scenario
is poor human-to-human transmission of H5N1 viruses,
which is attributed to the paucity of sialic acid a2,3
receptor in the epithelium of the human upper
respiratory tract, and the inability of the virus to replicate
efficiently at this site. Interestingly, the ISM approach
identifies important differences between H5N1 viruses
from Egypt. Some have the characteristics of most H5N1
strains whereas about one third of the viruses display
characteristics that are also found in human H1N1
seasonal virus. Interestingly the proportion of the latter
viruses has increased from 25 to about 50: between 2006
and 2007.
Similarly the results of H5N1 strains from Egypt (Figure
2) may be indicative of a possible viral evolution
towards receptor usage similar to that of H1N1 viruses,
which efficiently replicate in the upper respiratory tract.
The protein domain, which seems to be involved in this
subtle change, corresponds to amino acid domain 99–
132 (Figure 4g). However, the role of this domain for
enhanced infectivity in humans remains elusive. Inter-
estingly the corresponding domain of Spanish flu viruses
and Egypt-2 H5N1 viruses are much closer to the
receptor binding site of HA1 than in all other H1N1
and H5N1 viruses (Figures 4e–i and Table 2). This closer
proximity may indicate more efficient virus/receptor
interactions in these influenza viruses.
Finally, we will discuss some of recently reported
experimental results which point out functional and
immunological role of H5 HA domain encompassing
peptide VIN1. In order to identify mutations which
increase the recognition of H5 HA by SAa2,6Gal human
type receptor, Su and co-workers compared HA from A/
chicken/Ffujian/1042/2005 as wild type with isolates
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identified in both poultry and humans in mainland
China, Hong Kong, Thailand, and Vietnam during
outbreaks between 1996 and 2005 [29]. Unexpectedly,
this analysis revealed six amino acid substitutions
(K35R, D45N, D94N, K35R/D45N, K35R/45N/D94N,
A247T) outside the receptor-binding domain of HA,
which could enhance interaction between H5 HA and
human-type SAa2,6Gal receptor. As can be seen, three of
these mutations encompass mutation D45N which is
located within peptide VIN1 and two other mutations
(K35R and D94N) are located in its vicinity. It is the first
report that naturally occurring mutations in region of H5
HA which encompasses peptide VIN1 play an important
role in virus transmission from avian to human. It is of
note that Egyptian strains contain all of these mutations,
except mutation in position K35. These results point out
need for future testing of evolution of Egyptian strains
using hemiadsorption assays for HA receptor-binding
activity in order to identify possible new mutations in
this domain of HA which could increase affinity of
H5N1 viruses to human-type receptor.
Du and co-workers discovered monoclonal antibody
(MAb) 4G6 which efficiently and selectively recognizes
and neutralizes recently emerged Asian H5N1 viruses
[30]. The epitope-mapping analysis revealed that epitope
of the neutralizing 4G6 MAb is located within peptide
VIN1, pointing out this domain of HA as therapeutic and
diagnostic target for H5N1 viruses. The 4G6 MAb
recognizes residue D43 within peptide VIN1, which
characterizes Asian H5N1 viruses, but not N43 which
characterizes H5N2 and H5N1 viruses. It is also shown
that this MAb recognizes Egyptian H5N1 strains derived
from clade 2.2 containing D43. Based on these results,
Du and co-workers suggested that the 4G6 MAb could be
useful for rapid diagnosis of the infection of H5N1
currently circulating in Asia, Europe and Africa, as well as
for development of an antibody-based therapy. It is of
note that recent Egypt group-2 strains are characterized
by N43, in contrast to Egypt group-1 strains which
contain D43. It means that the 4G6 MAb can not be used
for detection and neutralization of H5N1 viruses
belonging to the Egypt group-2.
Conclusion
In summary, the presented results showed that: (i) H5N1
HA1 encode specific information represented by an IS
frequency different from that encoded by other subtypes;
(ii) this characteristic frequency is largely determined by a
highly conserved N-terminal domain of HA1; (iii) other
subtypes encode information that corresponds to other
domains including residues 262–295 for H1N1, residues
57–90 for H3N2, residues 28–61 for H7N7 and residues
87–120 for Spanish flu, (iv) at least in Egypt H5N1 viruses
have acquired features that may adapt them for H1N1-
like receptor usage possibly allowing more efficient
human-to-human transmission. Our results suggest
subtle but so far elusive differences in interactions of
these different viral subtypes with their receptors.
Collectively these results may help to better understand
the interaction of influenza virus with its receptor(s) and
to identify new targets for drug development.
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